High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

Kong, Grace; Johnston, Val; Ramdave, Shakher; Lau, Eddie; Rischin, Danny; Hicks, Rodney J.

doi:10.1089/cbr.2009.0644

Cited by 46 publications

(24 citation statements)

References 21 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest that In-111 octreotide can be safely used in the treatment of neuroendocrine tumors. In a recent study with combined use of In-111 octreotide and chemotherapy in 15 patients, even better results have been obtained (symptomatic improvement in 67 and stable disease in 90%) [33]. In the present study, the most frequent adverse effects were temporary reduction in lymphocyte count and nausea, with no remarkable renal or hematological toxicities.…”

Section: Discussionsupporting

confidence: 44%

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 44%

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

2011

View full text Add to dashboard Cite

show abstract

“…This is not surprising given the short particle range of the Auger electrons of 111 In and consequent lack of crossfire effects. In an attempt to increase the effectiveness of this therapy, radiosensitizing chemotherapy was added to this protocol with apparent enhancement in symptomatic and scintigraphic responses [11]. The cost and limited response rates of this therapy have, however, limited its ongoing use.…”

Section: Early Studies With [111in-dtpa⁰ Tyr3] Octreotidementioning

confidence: 99%

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

et al. 2017

Self Cite

View full text Add to dashboard Cite

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish ¹⁷⁷Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

show abstract

“…However, due to grade 3 capecitabine-induced angina, three patients discontinued the drug, but were able to complete the intended four cycles of PRRT (30). Feasible results were also published for the combination of capecitabine and 90 Y radioimmunotherapy and 111 In-octreotide radiopeptide therapy (31,32). The use of radiosensitizing agents is, therefore, not limited to the combination of one specific type of radionuclide.…”

Section: Prrt: Variantsmentioning

confidence: 99%

GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumors

Zwan

Bodei

Müeller-Brand

et al. 2015

European Journal of Endocrinology

111

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors (GEPNETs) patients. Most studies report objective response rates in 15-35% of patients. Also, outcome in terms of progression free survival (PFS) and overall survival compares very favorably with that for somatostatin analogs, chemotherapy, or new, 'targeted' therapies. They also compare favorably to PFS data for liverdirected therapies. Two decades after the introduction of PRRT, there is a growing need for randomized controlled trials comparing PRRT to 'standard' treatment, that is treatment with agents that have proven benefit when tested in randomized trials. Combining PRRT with liver-directed therapies or with targeted therapies could improve treatment results. The question to be answered, however, is whether a combination of therapies performed within a limited time-span from one another results in a better PFS than a strategy in which other therapies are reserved until after (renewed) tumor progression. Randomized clinical trials comparing PRRT with other treatment modalities should be undertaken to determine the best treatment options and treatment sequelae for patients with GEPNETs. European Journal of Endocrinology (2015) 172, R1-R8Invited Authors' profiles: Dik Kwekkeboom, MD works for the Department of Nuclear Medicine at the University Hospital, Erasmus MC, Rotterdam, The Netherlands. His major research interest is peptide receptor imaging and he coordinates the studies on therapy with the radiolabelled somatin analog 177 Lu-octreotate in patients with neuroendocrine tumors. He has numerous publications in international journals and textbooks, mainly in the field of endocrinology and peptide receptor scintigraphy and therapy.Wouter A van der Zwan currently works as research physician within the peptide receptor radionuclide therapy (PRRT) team at the Department of Nuclear Medicine of the Erasmus MC, Rotterdam and is directly involved in the treatment of patients affected by a Neuroendocrine Tumor with PRRT. Besides the clinical care of patients undergoing PRRT, his work includes conducting scientific research on the early and late effects, and optimization of PRRT. European Journal of EndocrinologyReview W A van der Zwan and others PRRT in neuroendocrine tumors 172:1 R1-R8

show abstract

High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

Cited by 46 publications

References 21 publications

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumors

Contact Info

Product

Resources

About